PRA Health Sciences, Inc. (PRAH): Price and Financial Metrics
PRA Health Sciences, Inc. (PRAH)
Today's Latest Price: $99.15 USD
Updated Sep 28 6:55pm
Add PRAH to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
PRAH Stock Summary
- PRAH has a higher market value than 80.38% of US stocks; more precisely, its current market capitalization is $6,222,768,220.
- PRAH's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 3,226 -- higher than 98.92% of US-listed equities with positive expected earnings growth.
- In terms of volatility of its share price, PRAH is more volatile than only 9.89% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to PRA Health Sciences Inc, a group of peers worth examining would be PLXS, HURN, EV, CRL, and PRFT.
- Visit PRAH's SEC page to see the company's official filings. To visit the company's web site, go to prahs.com.
PRAH Stock Price Chart Technical Analysis Charts
PRAH Price/Volume Stats
| Current price | $99.15 | 52-week high | $113.32 |
| Prev. close | $97.29 | 52-week low | $58.67 |
| Day low | $96.86 | Volume | 145,000 |
| Day high | $99.74 | Avg. volume | 420,085 |
| 50-day MA | $103.35 | Dividend yield | N/A |
| 200-day MA | $98.20 | Market Cap | 6.34B |
PRA Health Sciences, Inc. (PRAH) Company Bio
PRA Health Sciences provides various product development services for pharmaceutical and biotechnology companies worldwide. The company was founded in 1976 and is based in Raleigh, North Carolina.
PRAH Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $99.15 | $96.7 | -1% |
We started the process of determining a valid price forecast for PRA Health Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that PRA Health Sciences Inc ranked in the 44th percentile in terms of potential gain offered. In terms of the factors that were most noteworthy in this DCF analysis for PRAH, they are:
- The company has produced more trailing twelve month cash flow than 59.95% of its sector Healthcare.
- PRA Health Sciences Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than just 22.72% of tickers in our DCF set.
- PRA Health Sciences Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 5.69. This coverage rate is greater than that of 65.25% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -3% |
| 1% | -2% |
| 2% | -1% |
| 3% | 0% |
| 4% | 1% |
| 5% | 2% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as PRAH, try USPH, DXCM, DYNT, IART, and MOH.
Loading social stream, please wait...